Atmus Filtration Technologies (ATMU) Is Up 11.7% After Strong Q1, Buyback And New Supply Chain Chief - Has The Bull Case Changed?
Atmus Filtration Technologies, Inc. ATMU | 0.00 |
- Atmus Filtration Technologies recently reported first-quarter 2026 results showing higher sales and net income, reaffirmed its full-year net sales outlook, completed a share buyback tranche totaling 2,109,980 shares for US$87.98 million, and in May appointed Kevin Carpenter as Senior Vice President and Chief Supply Chain Officer.
- This combination of solid quarterly performance, continued capital returns, and a seasoned supply chain leader signals management’s focus on operational execution and supporting future growth initiatives.
- Against this backdrop, we’ll explore how reaffirmed 2026 guidance and a new Chief Supply Chain Officer may influence Atmus’s investment narrative.
The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Atmus Filtration Technologies Investment Narrative Recap
To own Atmus Filtration Technologies, you need to be comfortable with a filtration business that is still heavily tied to internal combustion engines and the aftermarket, while it works to broaden into industrial filtration. The latest results and guidance, plus the appointment of a Chief Supply Chain Officer, do not materially change the near term focus on integrating recent acquisitions and managing exposure to tariff and emissions related uncertainty.
The reaffirmed 2026 net sales outlook of US$1,945 million to US$2,015 million is the key near term reference point here, as it anchors expectations while Atmus absorbs the Cook Filter acquisition and refines its supply chain. The completed repurchase of 2,109,980 shares for US$87.98 million also gives context for how management is balancing investment in operations with returning capital at a time when structural shifts in engine technology remain a central risk.
Yet investors should also weigh how longer replacement cycles and electrification could affect Atmus’s high aftermarket exposure...
Atmus Filtration Technologies' narrative projects $2.2 billion revenue and $295.2 million earnings by 2029.
Uncover how Atmus Filtration Technologies' forecasts yield a $66.40 fair value, a 17% upside to its current price.
Exploring Other Perspectives
Three members of the Simply Wall St Community currently place Atmus’s fair value between US$50.83 and US$69.01, underscoring how far opinions can diverge. When you set those views against the company’s reliance on an evolving emissions and tariff backdrop, it becomes even more important to compare several perspectives before deciding how Atmus might fit in your portfolio.
Explore 3 other fair value estimates on Atmus Filtration Technologies - why the stock might be worth 10% less than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Atmus Filtration Technologies research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Atmus Filtration Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Atmus Filtration Technologies' overall financial health at a glance.
Searching For A Fresh Perspective?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Find 47 companies with promising cash flow potential yet trading below their fair value.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
